Comparison · NCT01716715-sae
Cabozantinib vs Paclitaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cabozantinib vs Paclitaxel: serious adverse events. Trial comparisons, record NCT01716715-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01716715-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.455 | 0.33 | 0.585 | wilson | |
| Risk in group 2 | 0.16 | 0.0834 | 0.285 | wilson | |
| Risk difference, group 1 minus group 2 | 0.295 | 0.118 | 0.446 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.84 | 1.41 | 5.71 | log | |
| Odds ratio, group 1 over group 2 | 4.38 | 1.74 | 11 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Cabozantinib than on Paclitaxel | 3.4 | 2.24 | 8.46 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cabozantinib | Cabozantinib 60 mg oral daily continously | 25 | 55 | EG000 |
| Group 2 | Paclitaxel | Paclitaxel 80mg/m2 administered weekly on days 1, 8 and 15 | 8 | 50 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- During study treatment through 30 days after treatment ends, an average of 2.5 years.
Source ClinicalTrials.gov
Trial
- Title
- Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- NCT number
- NCT01716715
- Phases
- PHASE2
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2020-03-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01716715?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01716715-sae